KIDSHealthcare · Medical DevicesThe 9 Wall Street analysts covering OrthoPediatrics Corp. hold a median 12-month price target of $25 — +14.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 8 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores OrthoPediatrics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (83): Sales and profits are climbing, and climbing faster than before.
Issuance (30): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KIDS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +14.9% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Sept 2026 | BTIG | Reiterates | Buy | $29 |
| 20 Aug 2026 | BTIG | Maintains | Buy | — |
| 20 Aug 2026 | BTIG | Maintains | Buy | $24 → $29 |
| 5 Aug 2026 | Needham | Maintains | Buy | $30 → $35 |
| 5 Aug 2026 | Needham | Maintains | Buy | — |
| 5 Aug 2026 | Piper Sandler | Reiterates | Overweight | $22 → $25 |
| 5 Aug 2026 | Piper Sandler | Reiterates | Overweight | — |
| 16 July 2026 | Truist Securities | Maintains | Hold | — |
| 16 July 2026 | Truist Securities | Maintains | Hold | $17 → $20 |
| 1 May 2026 | BTIG | Reiterates | Buy | — |
| 1 May 2026 | BTIG | Reiterates | Buy | $24 |
| 2 Mar 2026 | Truist Securities | Maintains | Hold | — |
| 27 Feb 2026 | BTIG | Maintains | Buy | — |
| 27 Feb 2026 | Needham | Maintains | Buy | — |
| 27 Jan 2026 | TD Cowen | Initiates | Buy | — |
| 10 Dec 2025 | Canaccord Genuity | Initiates | Buy | — |
| 29 Oct 2025 | BTIG | Reiterates | Buy | — |
| 29 Oct 2025 | Needham | Maintains | Buy | — |
| 10 Oct 2025 | BTIG | Maintains | Buy | — |
| 10 Oct 2025 | JMP Securities | Maintains | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KIDS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, OrthoPediatrics Corp. returned +20.2% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 3% of US stocks
Cheaper than 49% of US stocks
Cheaper than 50% of US stocks
Cheaper than 99% of US stocks
Higher than 63% of US stocks
Higher than 53% of US stocks
Higher than 87% of US stocks
Higher than 27% of US stocks
Higher than 17% of US stocks
Higher than 35% of US stocks
Higher than 35% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OrthoPediatrics Corp. has a market value of $586.9M and an enterprise value of $658.3M.
Revenue in the twelve months to 30 June 2026: $252.7M. The latest quarter grew 15.4% year on year.
Net income over the same four quarters: −$39.7M, a −15.7% net margin.
Diluted earnings per share, trailing twelve months: $−1.68.
Free cash flow in the twelve months to 30 June 2026: −$1.8M.
Trailing P/E: 246.3×; forward P/E: −30.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
OrthoPediatrics Corp. employs 602 people — $420K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own OrthoPediatrics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
OrthoPediatrics announced the launch of the OPSB® Knee 'TractorFIX contracture management orthosis, expanding its OrthoPediatrics Specialty Bracing portfolio.
Why it matters — The launch adds a new product to the company's pediatric-focused specialty bracing portfolio.
OrthoPediatrics sponsored the 10th Pediatric Orthopedic Surgical Techniques Course, a milestone program that achieved record attendance with 39 participants from 23 institutions across 22 cities and three countries.
Why it matters — The company's sponsorship of the record-attendance educational course supports its engagement with the pediatric orthopedic community and helps build brand awareness among practitioners.
OrthoPediatrics announced that it recently performed the 1,000th Tibia Nail implantation using its latest Pediatric Nailing Platform (PNP). The company, which focuses exclusively on pediatric orthopedics, shared this milestone via a press release.
Why it matters — Crossing the 1,000-implantation milestone suggests growing clinical adoption of the company's pediatric nailing platform.
OrthoPediatrics announced the full commercial launch of its 3P Pediatric Plating Platform Hip System, following a successful limited launch with more than 350 implantations. The launch reflects demand for the company's pediatric-specific hip plating technology.
Why it matters — This marks the transition of a new pediatric-specific hip product to wider commercial availability, expanding OrthoPediatrics' core product lineup.
OrthoPediatrics reported record revenue, adjusted EBITDA and number of children helped in Q2, with CEO Dave Bailey noting at the Canaccord Genuity Growth Conference that the company is seeing early contributions from its newer "super cycle" products, marking an inflection point.
Why it matters — The record results and early contributions from new "super cycle" products signal that OrthoPediatrics may be entering a period of accelerated growth, which is important for investors watching the company's trajectory.
The 9 Wall Street analysts covering OrthoPediatrics Corp. have a median 12-month price target of $25, with estimates ranging from $22 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering OrthoPediatrics Corp., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OrthoPediatrics Corp. 62 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, OrthoPediatrics Corp. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (83 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +14.9% from the last close, and Ticker Nerd's factor model ranks OrthoPediatrics Corp. 62 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering OrthoPediatrics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KIDS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $35 over the next 12 months.
OrthoPediatrics Corp. returned +20.2% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
OrthoPediatrics Corp. is a medical device company focused exclusively on pediatric orthopedics.
The most recent item we track (GlobeNewsWire, 7 Oct 2026): "OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX". OrthoPediatrics announced the launch of the OPSB® Knee 'TractorFIX contracture management orthosis, expanding its OrthoPediatrics Specialty Bracing portfolio.
OrthoPediatrics Corp. is a medical device company focused exclusively on pediatric orthopedics. It designs, develops, and markets anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions, supporting surgeons and caregivers in treating trauma and deformity correction, scoliosis, and sports medicine cases. The company’s product portfolio includes surgical systems, pediatric nailing solutions, spinal care products, and specialty bracing technologies tailored to the needs of smaller and developing patients. OrthoPediatrics also operates orthopedic and prosthetic clinic services, extending its role beyond products to non-surgical care. Its business is centered on serving hospitals, children’s medical centers, and orthopedic specialists in the United States and international markets. Headquartered in Warsaw, Indiana, OrthoPediatrics occupies a specialized position in the medical technology market as a pediatric-only orthopedic platform.
CEO Mr. David R. Bailey · 602 employees · United States · https://www.orthopediatrics.com
